Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 11NIH 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 6Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Lymphoma, Non-Hodgkin 5Carcinoma, Renal Cell 5Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Cancer Metastatic 1Neuroblastoma 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × aldesleukin × Clear all
NCT01592045 2015-09-23

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

United Therapeutics

Phase 1/2 Completed
28 enrolled 11 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡